CMT1A duplicated region transcript 15Genealiases: []
Q-omics provides the consensus-scored CDRT15 profile across patient tissues and cancer cell-line models. CDRT15 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CDRT15 is differentially expressed in 7, with the highest sampling consensus in STAD. Additionally, CDRT15 RNA expression shows 11,751 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, STAD, and UVM as cancer lineages where CDRT15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDRT15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDRT15 survival associations across molecular data types. CDRT15 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDRT15 RNA expression–survival associations across cancer types. High CDRT15 expression shows unfavorable associations in KIRC, CHOL, ACC, KICH, SKCM and DLBC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CDRT15 RNA expression.
This table summarizes CDRT15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for CDRT15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDRT15 shows higher tumor expression in STAD, CHOL, LUSC, UCEC, PRAD and BRCA. The STAD box plot shows higher CDRT15 RNA expression in tumor versus normal tissue (log2 FC = +0.324, t-test p = .002).
This table shows molecular features associated with CDRT15 in patient tissues and cancer cell lines. In patient samples, CDRT15 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CDRT15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
